Skip to main content

Drug Interactions between trichophyton skin test and typhoid vaccine, live

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

typhoid vaccine, live trichophyton skin test

Applies to: typhoid vaccine, live and trichophyton skin test

ADJUST DOSING INTERVAL: Reactivity to diagnostic skin test antigens may be temporarily depressed in patients who have recently been vaccinated with live, attenuated viral or bacterial vaccines, potentially resulting in a false negative reaction. The mechanism of this interaction is not well described, but may involve live vaccine-mediated suppression of the immune system, possibly via inhibition of the lymphocyte mitotic response. Clinical data are limited. In one study, 26 tuberculin-positive children were vaccinated with the live, attenuated mumps virus vaccine. A tuberculin skin test was administered on day 1 and then every 7 days for 4 doses, with the magnitude of induration measured 48 hours after each skin test. The mumps vaccination was given on day 3 of the study. A significant decrease in the tuberculin reaction was observed in 17 of the 26 children. Delayed hypersensitivity to the tuberculoprotein virtually disappeared within 2 weeks of the live, attenuated mumps vaccine for many of these children and for some the depression of delayed hypersensitivity persisted through the 4-week observational period. A similar response was also reported in a separate study of 15 children with tuberculosis who developed mild cases of measles following vaccination with the live measles vaccine, with or without gamma globulin. The tuberculin skin test was documented as negative often during the measles incubation period and frequently observed to be negative during the first week of measles symptoms in these children. While this reaction has only been reported clinically in patients receiving the tuberculin skin test with certain live, attenuated viral vaccines, it may also apply to other skin tests and live, attenuated bacterial vaccines as well.

MANAGEMENT: Clinicians should be aware of the potential for falsely insignificant or false-negative results when performing delayed-hypersensitivity skin testing on patients who have recently received live, attenuated viral or bacterial vaccines. In general, tuberculin skin tests can be administered before a live vaccine, given simultaneously with the live vaccine at separate sites (preferred option), or the tuberculin skin test should be postponed for at least 4 weeks after immunization. For the live, non-replicating smallpox and monkeypox vaccine, some authorities recommend following the same guidelines that are recommended for other live vaccines with the tuberculin skin test; however, if a delay in the tuberculin skin test would cause a substantial burden for the patient, they state that any sequence of vaccination and tuberculin skin test is acceptable. Although not addressed in the labeling for other diagnostic skin tests, these recommendations should be considered when evaluating skin testing and administration of live vaccines. Local vaccination guidelines and prescribing information for both the vaccine(s) and individual skin test(s) should be consulted for further guidance.

References (18)
  1. (2001) "Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen)." Aventis Pharmaceuticals
  2. (2001) "Product Information. Multitest CMI (skin test antigens, multiple)." Aventis Pharmaceuticals
  3. "Product Information. Tuberculin Tine Test (tuberculin purified protein derivative)." Connaught Laboratories Inc
  4. Kroger A, freedman m CDC Yellow Book: Vaccination and Immunoprophylaxis - General principles https://wwwnc.cdc.gov/travel/yellowbook/2024/preparing/vaccination-and-immunoprophylaxis-general-principles#spacing
  5. Australian Government. Department of Health and Aged Care Australian Immunisation Handbook: Tuberculosis https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/tuberculosis
  6. (2023) "Product Information. Spherusol (coccidioidin skin test)." Nielsen Biosciences Inc
  7. (2021) "Product Information. Candin (candida albicans extract)." Nielsen Biosciences Inc
  8. (2021) "Product Information. Tubersol (tuberculin purified protein derivative)." sanofi pasteur
  9. (2013) "Product Information. Aplisol (tuberculin purified protein derivative)." JHP Pharmaceuticals
  10. (2007) "Product Information. Trichophyton Extracts (trichophyton skin test)." Allermed Laboratories Inc
  11. Australian Government. Department of Health and Aged Care (2025) A tuberculin skin test (TST; Mantoux) before BCG vaccination is only recommended in certain circumstances, based on risk factors for previous tuberculosis exposure. https://immunisationhandbook.health.gov.au/recommendations/a-tuberculin-skin-test-tst-man
  12. UK Health Security Agency (2025) Tuberculosis (TB) testing and potential interactions with COVID-19 vaccinations. https://www.nhshealthatwork.co.uk/images/library/files/Bulletins/20211026_BN2021-060_Tuberculosis_testing_and_potential_interactions_with_COVID-19_vaccinations.pdf
  13. UK Health Security Agency (2025) Tuberculosis: the green book, chapter 32 https://www.gov.uk/government/publications/tuberculosis-the-green-book-chapter-32
  14. Kupers TA, Petrich JM, Holloway AW, St. Geme JW (1970) "Depression of tuberculin delayed hypersensitivity by live attenuated mumps virus." J Pediatr, 76, p. 716-21
  15. starr se (1996) "Novel mechanism of immunosuppression after measles." Lancet, 348, p. 1257-8
  16. starr s, Berkovich S (1964) "Measles vaccine and the tuberculin test." N Engl J Med, 270, p. 422-3
  17. CDC (2025) Jynneos vaccine additional considerations for intradermal administration. https://www.cdc.gov/mpox/hcp/vaccine-considerations/intradermal-administration.html
  18. Miller E, Wodi AP (2025) Chapter 2: general best practice guidance for immunization https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-2-general-best-practice-guidance.html

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.